Lucky Core Industries Rejects Reports of Divesting Pharmaceutical Operations

PAKISTAN

Lucky Core Industries Limited (LCI), formerly ICI Pakistan Ltd., has strongly refuted recent media reports claiming that several global pharmaceutical companies— including LCI—have divested their local manufacturing operations over the past three years.

In its posting to the PSX, the company stated that its pharmaceutical manufacturing operations “continue to operate in the ordinary course of business” and that it has not divested any pharmaceutical manufacturing units during the last three years.

Contrary to the reports, LCI emphasized that it has in fact expanded its footprint in the pharmaceutical sector. The most recent addition to its portfolio was the acquisition of assets from Pfizer Pakistan Limited and other Pfizer group entities, a transaction completed in September 2024. This strategic move underscores the company’s ongoing commitment to strengthening its pharmaceutical capabilities in Pakistan.

LCI reaffirmed its dedication to the country’s healthcare sector, noting that it remains focused on innovation, geographic expansion, and improving access to quality healthcare solutions. The company reiterated its long-term commitment to patients, partners, and stakeholders, underscoring that its growth trajectory in the pharmaceutical segment remains strong and forward-looking. – ER News Desk

READ MORE STORIES